Adapting the GLP-1-signaling system to the treatment of type 2 diabetes

Current Diabetes Reviews

Volumn 3, Issue 1, 2007, Pages 15-23

  Salvatore, Teresa ^a,b   Carbonara, Ornella ^a   Cozzolino, Domenico ^a   Torella, Roberto ^a   Carlo Sasso, Ferdinando ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NONE   (Italy)

Author keywords

DPP IV inhibitors; GLP 1R agonists; Glucagon like peptide 1; Incretin effect; Type 2 diabetes

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALBUGON; ANTIDIABETIC AGENT; CANDOXATRIL; CJC 1131; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPOR AGONIST; INCRETIN; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PLACEBO; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; VIDAGLIPTIN; VILDAGLIPTIN;

BINDING AFFINITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DRUG ABSORPTION; DRUG DOSE TITRATION; DRUG HALF LIFE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTIGENS, CD26; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MALEIMIDES; PEPTIDES; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION;

EID: 34247111220     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339907779802076     Document Type: Review

References (109)

1. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999; 20: 876-913.
2. Moore B, Edle E, Abram J. On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane. Biochem J 1906; 1: 28-38.
3. Zunz E, La Barre J. Contributions à l'étude des variations physiologiques de la sécrétion interne du pancréas: rélations entre les sécrétions externe et interne du pancréas. Arch Int Physiol Biochim 1929; 31: 20-44.
4. Elrick H, Stimmler L, Hlad CJ, Arai Y. Plasma insulin responses to oral and intravenous glucose aministration. J Clin Endocrinol Metab 1964; 24: 1076-1082.
5. McIntyre N, Holdsworth CD, Turner DA. New interpretation of oral glucose tolerance. Lancet 1964; 2: 20-21.
6. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492-8.
7. Meier JJ, Nauck MA, Schmidt WE, Gallwitz B. Gastric inhibitory polypeptide: The neglected incretin revisited. Regul Pept 2002; 107: 1-13.
8. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 1987; 2: 1300-4.
9. Holst JJ, Bersani M, Johnsen AH, Kofod H, Hartmann B, Orskov C. Proglucagon processing in porcine and human pancreas. J Biol Chem 1994; 269: 18827-33.
10. Takeda J, Seino Y, Tanaka K, et al. Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor. Proc Natl Acad Sci USA 1987; 84: 7005-8.
11. Yip RG, Wolfe MM. GIP biology and fat metabolism. Life Sci 2000; 66: 91-103.
12. Trumper A, Trumper K, Trusheim H, Arnold R, Goke B, Horsch D. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signalling. Mol Endocrinol 2001; 15: 1559-70.
13. Trumper A, Trumper K, Horsch D. Mechanisms of mitogenic and anti-apoptotic signalling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J Endocrinol 2002; 174: 233-46.
14. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagons-like peptide-1 (7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829-35.
15. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000; 85: 3575-81.
16. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-7.
17. Meier JJ, Gallwitz B, Kask B, et al. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes 2004; 53 (Suppl 3): S220-4.
18. Lynn FC, Pamir N, Ng EH, McIntosh CH, Kieffer TJ, Pederson RA. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 2001; 50: 1004-11.
19. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929-40.
20. Krarup T. Immunoreactive gastric inhibitory polypeptide. Endocr Rev 1988; 9: 122-34.
21. Jones IR, Owens DR, Luzio S, Hayes TM. Glucose dependent insulinotropic polypeptide (GIP) infused intravenously is insulinotropic in the fasting state in type 2 (non-insulin dependent) diabetes mellitus. Horm Metab Res 1989; 2: 23-6.
22. Nauch M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2(non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52.
23. Jones IR, Owens DR, Vora J, Luzio SD, Hayes TM. A supplementary inffusion of glucose-dependent insulinotropic polypeptide (GIP) with a meal does not significantly improve the beta cell response or glucose tolerance in type 2 diabetes mellitus. Diabetes Res Clin Pract 1989; 7: 263-9.
24. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002; 45: 1111-9.
25. Meier JJ, Hucking, K, Holst JJ, Deacon CF, Schmiegel WH, Nauck MA. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 2001; 50: 2497-504.
26. Ben GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preproglucagan gene. Nature 1983; 304: 368-71.
27. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci I, Habener JF. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 1986; 261: 11880-9.
28. Yoshimoto S, Hirota M, Ohboshi C, Shima R. Identification of glucagons-like peptide-1 (7-36) amide in rat brain. Ann Clin Biochem 1989; 26: 169-71.
29. Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagon-like peptide 1(7-36)amide and glucagon-like peptide 1(7-37) in healthy subjects are indistinguishable. Diabetes 1993; 42: 658-61.
30. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeltd W. Normalization of fasting hyperglycaemia by exogenous lucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-4.
31. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 1994; 43: 535-9.
32. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (1-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 1993; 138: 159-66.
33. Eissele R, Goke R, Willemer S, et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. J Clin Invest 1992; 22: 283-91.
34. De Léon DD, Crutchlow MF, Ham J-YN, Stoffers DA. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. Int J Biochem Cell Biol 2006; 38: 845-59.
35. Hermann C, Goke R, Richter G, Fehmann HC, Arnold R, Goke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995; 56: 117-26.
36. Gentilcore D, Chaikomin R, Jones KL, et al. Effects of fat on gastric emptying of and the glycemic, insulin, and incretin responses to a carbohydrate meal in type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 2062-7.
37. Feinle C, O'Donovan D, Daran S, et al. Effects of fat digestion on appetite, APD motility, and gut hormones in response to duodenal fat infusion in humans. Am J Physiol 2003; 284: C798-C807.
38. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126-31.
39. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dypeptidyl peptidase IV. Endocrinology 1995; 136: 3585-96.
40. Vahl TP, Paty BW, Fuller BD, Prigeon RL, D'Alessio DA. Effects of GLP-1-(7-37), and GLP-1-(9-36)NH(2) on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 2003; 88: 1772-9.
41. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-1(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999; 140: 5356-63.
42. Hansen L, Hartmann B, Bisgaard T, Mineo H, Jørgensen PN, Holst JJ. Somatostatin restrains the secretion of glucagon-like peptide-1 and 2 from isolated perfused porcine ileum. Am J Physiol 2000; 278: E1010-8.
43. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 1996; 2713: E458-64.
44. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, et al. Characterization of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for the other glucagon-like peptides. Regul Pept 1995; 58: 149-56.
45. Hupe-Sodmann K, Goke R, Goke B, et al. Endoproteolysis of glucagon-like peptide (GLP)-1 (7-36) amide by ectopeptidases in RINm5F cells. Peptides 1997; 18: 625-32.
46. Deacon CF. Therapeutic strategies based on glucagon-like peptide-1. Diabetes 2004; 53: 2181-9.
47. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagons-like peptide 1. Proc Natl Acad Sci U S A 1992; 89: 8641-45.
48. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996; 137: 2968-78.
49. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69-72.
50. Seeley RJ, Blake K, Rushing PA, et al. The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride. J Neurosci 2000; 20: 1616-211.
51. Nishizawa M, Nakabayashi H, Kawai K. The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor. J Auton Nerv Syst 2000; 80: 14-21.
52. Montrose-Rafizadeh C, Yang H, Rodgers BD, Beday A, Pritchette LA. High potency antagonists of the pancreatic glucagons-like peptide-1 receptor. J Biol Chem 1997; 272: 21201-6.
53. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide-1 stimulates insulin gene expression and increases cyclic AMP levels in rat islet cell line. Proc Natl Acad Sci U S A 1987; 84: 3434-8.
54. Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide-1(7-37) stimulation of proinsulin gene expression and proinsulin byosynthesis in insulinoma beta TC1 cells. Endocrinology 1992; 130: 159-66.
55. Wang Y, Perfetti R, Greig NH, et al. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Invest 1997; 99: 2883-9.
56. Holz GG, Chepumy OG. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem 2003; 10: 2471-83.
57. Nauck MA, Helmesaat MM, Behele K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycermic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87: 1239-76.
58. Perfetti R, Hui H. The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res 2004; 36: 804-10.
59. Heller RS, Kieffer TJ, Habener JF. Insulinotropic glucagon-like peptide 1 receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes 1997; 46: 785-91.
60. Fehmann HC, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide. Endocr Rev 1995; 16: 390-410.
61. Nauk MA, El-Ouaghlidi A, Homepesch M, Jacobsen J, Elbroend B. No impairment f hypoglycemia counterregulation via glucagon with N2211, a GLP-1 derivative, in subjects with type 2 diabetes. Diabetes 2003; 52: A128.
62. Schirra J, Houck P, Wank U, Arnold R, Goke B, Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on antro-pyloroduodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut 2000; 46: 622-31.
63. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol Gastrointest Liver Physiol 1997; 273: G920-7.
64. Wettergren A, Wojdemann M, Holst JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol Gastrointest Liver Physiol 1998; 275: G984-92.
65. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-30.
66. Orskov C, Poulsen SS, Moller M, Holst JJ. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 1996; 45: 832-5.
67. Vrang N, Phifer CB, Corkem MM, Berthoud HR. Gastric distension induces c-Fos in medullary GLP-1/2-containing neurons. Am J Physiol 2003; 285: R470-8.
68. Baggio LL, Huang Q, Brown TJ, Drucker DJ. A recombinant human glucagon-like peptide (GLP)-1 albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 2004; 53: 2492-500.
69. Prigeon RL, Quddusi S, Paty B, D'Alessio DA. Suppression of endogenous glucose production by glucagon-like peptide 1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol 2003; 285: E701-7.
70. D'Alessio DD, Vahl T, Prigeon R. Effects of glucagon-like peptide 1 on the hepatic glucose metabolism. Horm Metab Res 2004; 36: 837-41.
71. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50: 609-13.
72. Toft-Nielsen MB, Madsbad S, Holst JJ. Determinants of the effectiveness of glucagons-like peptide-1 in type 2 patients. J Clin. Endocrinol Metab 2001; 86: 3853-60.
73. Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003; 52: 380-6.
74. Henquin J-C, Boitard C, Ferrannini E, Steiner DF, Efendic S. Editorial: Impact of treatment on islet function in type 2 diabetes. Diabetes 2004; 53: S1-S5.
75. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004; 287: E199-E206.
76. Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003; 26: 2370-7.
77. Edwards CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281: E155-61.
78. Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002; 87: 1282-90.
79. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082-9.
80. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-35.
81. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-100.
82. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-91.
83. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med 2005; 143: 559-69.
84. Gedulin BR, Smith P, Prickett KS. Dose-response for glycaemic and metabolic change 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. Diabetologia 2005; 48: 1380-5.
85. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43: 1664-9.
86. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodinamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45: 195-202.
87. Elbrond B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002; 25: 1398-404.
88. Feinglos MN, Saad MF, Pi-Sunyiert FX, An B, Santiago O. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycemic control and bodyweight in subjects with type 2 diabetes. Diab Med 2005; 22: 1016-23.
89. Lawrence B, Dreyfus JF, Wen S, Guivarc'h PH, Drucker DJ, Castaigne JP. CJC 1131 a long acting GLP-1 derivative exhibits an extended pharmacokenetic profile in healthy human volunteers. In: American Diabetes Association 63rd Annual Meeting, 2003; 534-P (p.A125).
90. Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diab Metab Res Rev 2004; 20: 411-7.
91. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomised, controlled trial. Diabetes Care 2004; 27: 1335-42.
92. Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect on glucagon-like peptide-1 in anesthetized pigs. Diabetes 1998; 47: 764-9.
93. Pospisilik JA, Stafford SG, Demuth HU, et al. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 2002; 51: 943-50.
94. Ahren B, Holst JJ, Martensson H, Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 2000; 404: 239-45.
95. Ahrén B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002; 25: 869-75.
96. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078-84.
97. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2874-80.
98. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance tests in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91(11): 4612-9.
99. Herman GA, Bergman A, Yi B, Kipnes M. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin 2006; 22: 1939-47.
100. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-23.
101. Mest H-J, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 2005; 48: 616-20.
102. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003; 40: 209-94.
103. Fleicher B. CD26: a surface protease involved in T-cell activation. Immunol Today 1994; 15: 180-4.
104. Yan S, Marguet D, Dobers J, Reutter W, Fan H. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. Eur J Immunol 2003; 33: 1519-27.
105. Plamboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 2005; 48: 1882-90.
106. Plamboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both involved in regulating the metabolic stability of glucagon-like peptide-1 in vivo. Adv Exp Med Biol 2003; 524: 303-12.
107. Oefner C, Pierau S, Dale GE. Ectopeptidase and type II diabetes. 11th Protein Structure Determination in Industry, Cambridge, 2003 (Abstract T001).
108. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2874-80.
109. De Fronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-100.